Endocrine toxicities of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab,...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Endocrinology Vol. 17; no. 7; pp. 389 - 399
Main Authors:	Wright, Jordan J, Powers, Alvin C, Johnson, Douglas B
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.07.2021
Subjects:	Adrenal glands Adverse events Antineoplastic Agents, Immunological - adverse effects Cancer Cell activation CTLA-4 protein Cytotoxicity Diabetes mellitus Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - immunology Endocrine disorders Endocrine System Diseases - chemically induced Endocrine System Diseases - diagnosis Endocrine System Diseases - epidemiology Endocrine System Diseases - therapy Epidemiology Humans Hypothyroidism Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune System - drug effects Immune System - physiology Immunotherapy Immunotherapy - adverse effects Lymphocytes T Monoclonal antibodies Morbidity Neoplasms - drug therapy Neoplasms - epidemiology Neoplasms - immunology Pancreas PD-1 protein Pembrolizumab Pituitary Signal transduction Thyroid Thyrotoxicosis
ISSN:	1759-5029, 1759-5037, 1759-5037
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!